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Enzyme replacement therapy with agalsidase beta in kidney
transplant patients with Fabry disease: A pilot study.
Background. We sought to assess the safety and efficacy of
enzyme replacement therapy (ERT) with recombinant human-
a-galactosidase A (rh-a-Gal A) in kidney transplant recipients
with Fabry disease, a previously unstudied population.
Methods. Three male kidney transplant recipients with
biochemically, genetically, and histologically confirmed Fabry
disease and documented Fabry myocardiopathy received the
rh-a-Gal A, agalsidase beta, 1 mg/kg of body weight every
2 weeks by intravenous infusion and were monitored biochem-
ically, clinically, and electrocardiographically and echocardio-
graphically for 18 months.
Results. Patients showed biochemical, clinical/functional,
and morphologic response to ERT. Plasma globotriaosylce-
ramide decreased 23% to 50%. Extremity pain resolved within
2 months in the patient with this manifestation. On echocar-
diography, left ventricular mass, end diastolic diameter (EDD),
and cardiac contractility, shown by ejection fraction (EF), im-
proved in 2 of the 3 patients receiving essentially all planned
infusions. EDD and EF remained basically stable, but cardiac
morphologic abnormalities progressed in the other patient, who
had a 5-month interruption in ERT after the initial month. Mild
mitral insufficiency persisted in all patients, as did atrial fibril-
lation in the affected individual. After a combined total of 116
infusions, no treatment-related adverse event, intolerance, or
seroconversion was seen. Renal function remained stable and
the immunosuppression regimen unchanged in all patients.
Conclusion. Our pilot study provides preliminary evidence
that ERT with agalsidase beta, 1 mg/kg every 2 weeks, is safe
and often effective against extra-renal manifestations in kid-
ney transplant patients with Fabry disease. Studies with longer
courses of this and higher doses of ERT are merited in this
population.
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Fabry disease is a rare, life-shortening, X-linked re-
cessive disorder resulting from deficient activity of the
lysosomal enzyme, a-galactosidase A (a-Gal A) [1]. The
enzymatic defect leads to progressive accumulation of
the glycosphingolipid globotriaosylceramide (Gb3) in all
body fluids, and in viscera including the vascular en-
dothelium, kidney, heart, connective tissue, and periph-
eral nerves.
The most common presenting symptoms are painful
paresthesias in the extremities, fever, hypohydrosis, an-
giokeratoma, and corneal opacities (cornea verticillata).
In males with classic Fabry disease, clinical kidney in-
volvement, most often heralded by the onset of protein-
uria, usually begins by the fourth decade [2, 3]. Fabry
nephropathy typically progresses by the fifth decade to
end-stage renal disease requiring hemodialysis and/or
kidney transplantation.
Clinical cardiac involvement is another frequent later
feature of Fabry disease. Gb3 deposition involves car-
diac conduction tissue, muscle, and valves, resulting
in arrhythmias, congestive heart failure, or myocardial
infarction [4, 5]. In addition to arrhythmias, electrocar-
diography may show a shortened P-R interval. Echocar-
diography demonstrates an increased incidence of mitral
insufficiency, left ventricular hypertrophy (LVH) with in-
creased left ventricular mass (LVM), as well as increased
interventricular septum thickness (ST), left ventricular
posterior wall thickness (PWT), and end diastolic diam-
eter (EDD) [4–6].
Kidney transplantation successfully corrects Fabry re-
nal failure, resulting in a good graft and patient sur-
vival [7–11]. Nevertheless, despite the normalization of
renal function after transplantation, serious aspects of
Fabry disease, such as myocardial involvement, some-
times persist and progress [12, 13]. Indeed, together with
cerebrovascular events, late cardiologic complications
comprise the main cause of the high morbidity and mor-
tality in Fabry patients receiving renal replacement [8, 9,
11, 14, 15].
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Table 1. Pretreatment patient characteristics
Characteristic Patient 1 Patient 2 Patient 3
Nephrology department Rimini Pisa Cesena
Age years 49 35 58
Weight kg 79 69 70
a-galactosidase-A activity in leukocytesa 0.08 0.09 0.102
lmol/mg/hr (normal, 1.20 to 1.65 lmol/mg/hr)
Fabry genotype Exon 7 (I354K) Exon 4 (R227Q) Exon 6 (I317T)
Months between transplantation and initiation 110 43 23
of ERT
Interruption in treatment None 5 months’ interruption after None
initial month of treatmentb
Total infusions received 42 30 44
Total dose infused 2940 mg 2100 mg 3080 mg
Immunosuppressive regimen Ste, CyA, Az Ste, CyA Ste, Tac
Abbreviations are: Az, azathioprine; CyA, cyclosporine; ERT, enzyme replacement therapy; Ste, steroids; Tac, tacrolimus.
aAssayed with 4-methylumbelliferyl-galactosidase.
b Treatment was interrupted after an episode of gastroenteritis accompanied by functional ARF that did not require hemodialysis, attributed to a viral infection and
consequent dehydration.
Historically, treatment of Fabry disease has been non-
specific and palliative [14–16]. Recently, a targeted treat-
ment for Fabry disease, enzyme replacement therapy
(ERT) with recombinant human a–Gal A, was approved
in Europe and the United States after randomized clini-
cal trials demonstrated its safety and efficacy in reducing
or clearing Gb3 storage from a variety of organs, tissues,
and cell types [16, 17], and in ameliorating neuropathic
pain [18].
These clinical trials were conducted in patients with
normal renal function or mild chronic renal failure. Al-
though general opinion holds that ERT should benefit
Fabry kidney transplant recipients by preventing late car-
diologic and cerebrovascular complications [3, 15], its
safety and efficacy in such patients heretofore have not
been evaluated. We therefore undertook a pilot multi-
center clinical study of ERT with the recombinant human
a–Gal A, agalsidase beta, in 3 patients with a functioning
allograft and with Fabry disease including myocardiopa-
thy. We now report 18-month follow-up from this trial.
METHODS
Patients
We recruited 3 male kidney transplant recipients with
biochemically, molecularly, and histologically confirmed
Fabry disease including myocardiopathy, documented be-
fore or after transplantation, from renal units in Northern
Italy. These patients had initiated dialysis between 1992
and 1999 and received kidney transplantation in 1993 [pa-
tient (Pt)1], 1999 (Pt 2), or 2000 (Pt 3). After the trans-
plant, Pts 1 and 3 had stable renal function; in Pt 2, an
acute rejection occurred 1 month after transplantation
and 27 months before initiation of ERT. This patient was
treated with 3 boluses of methylprednisolone and OKT3
monoclonal antibodies (Orthoclone; Ortho Laborato-
ries, New Brunswick, NJ, USA), with a plasma creatinine
of 2 mg/dL 2 months after rejection.
Pt 1 experienced recurrence of extremity pain and on-
set of severe arrhythmia (atrial fibrillation) 8 years after
kidney transplantation; a cardiac biopsy specimen ob-
tained at that time showed massive Gb3 deposition in
myocytes. In Pt 2, cardiomyopathy was documented al-
most 1 year after transplantation, by detection of severe
right and LVH on echocardiography. In Pt 3, Fabry car-
diomyopathy was histologically documented before kid-
ney transplantation, through analysis of a specimen from
a biopsy performed because of presence of right branch
block, LVH, and mitral insufficiency on electrocardiog-
raphy and echocardiography. Table 1 shows additional
patient characteristics.
Cardiologic and biochemical evaluation
Cardiologic evaluation took place at each patient’s
medical center according to standard criteria. Echocar-
diography was performed by the same operator and on
the same equipment immediately before the first infusion,
and after every 12 and 18 months of ERT with conven-
tional M-mode echo-Doppler with a four-chamber tech-
nique. Determination of Gb3 concentration in plasma and
urine samples was performed at the Mass Spectrometry
Center of the University of Florence at the same intervals,
using the tandem mass spectrometric method of Boscaro
et al [19]. At baseline and periodically thereafter, pres-
ence of antibody against recombinant human a–Gal A
was assessed by the enzyme manufacturer via a specific
enzyme-linked immunosorbent assay (ELISA), with con-
firmation of positive results by radioimmunoprecipita-
tion assay, using methodology based on that described
elsewhere [20].
ERT
Each patient received agalsidase beta (Fabrazyme;
Genzyme Corp., Cambridge, MA, USA), 0.9 to 1 mg/kg
of body weight by intravenous infusion every 2 weeks.
Infusion time initially was 4 hours, but after the first
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Table 2. Clinical and laboratory characteristics at baseline and after 18 months of follow-up
Patient 1 Patient 2a Patient 3
Characteristic Baseline 18 months Baseline 18 months Baseline 18 months
Pain and paresthesias +++ — — — — —
Serum creatinine, mg/dL (normal, 0.6 to 1.3 mg/dL) 1.9 2.0 3.5 3.2 1.5 1.4
Urinary protein mg/day (normal, ND) ND ND ND ND 550 ND
Plasma Gb3 ng/lL 3.16 1.57 6.41 4.94 8.27 4.40
Urinary Gb3 ng/lL ND ND ND ND ND ND
Abbreviations are: Gb3, globotriaosylceramide; ND, not detectable; —, absent; +++, present.
aPatient 2 received a total of 13 months of ERT during the follow-up period because of an interruption in treatment after the initial month.
Table 3. Electrocardiographic and echocardiographic findings at baseline and after 18 months of follow-up
Patient 1 Patient 2a Patient 3
Finding Baseline 18 months Baseline 18 months Baseline 18 months
P-R interval msec (normal, >130 msec) 134 143 170 168 142 144
EF % (normal, >45%) 40.0 54.0 65.2 64.0 47.0 55.4
EDD cm (normal, 3.0 to 5.0 cm) 5.80 5.70 5.95 5.80 5.30 5.20
ST cm (normal, 0.8 to 1.0 cm) 1.80 1.70 1.35 1.80 2.60 2.40
PWT cm (normal, 0.7 to 1.1 cm) 1.30 1.20 1.19 1.70 2.30 2.20
LVMb g (normal, 250 to 330 g) 558.2 402.4 403.8 512.1 934.6 832.1
Legend: EDD = end diastolic diameter, EF = ejection fraction, LVM = left ventricular mass, PWT = posterior wall thickness, ST = septum thickness.
aPatient 2 received a total of 13 months of ERT during the follow-up period because of an interruption in treatment after the initial month.
bCalculated according to the formula 1.04 × ((EDD + ST + PWT)3 – EDD3) − 13.6.
month of ERT was decreased by 15 minutes per infusion
until in the sixth month of treatment, when it reached
its present duration of 2 hours. If clinically warranted,
treatment could be interrupted or discontinued be-




Clinical and laboratory characteristics of the 3 pa-
tients at baseline and after 18 months of ERT are shown
in Table 2. In Pt 1, extremity pain disappeared within
2 months of the beginning of therapy. All patients had sta-
ble, if not slightly improved renal function, as reflected by
serum creatinine values. No changes in immunosuppres-
sive regimen have been necessary. Proteinuria remains
absent in Pts 1 and 2, while in Pt 3, the mild protein-
uria present at baseline resolved after 10 months of ERT.
Plasma Gb3 concentration was reduced by 23% to 50%
after 18 months of ERT. In all patients, Gb3 was unde-
tectable in the urine at baseline and remained so after
1.5 years of ERT.
Table 3 shows electrocardiograhic and echocardio-
graphic findings in the 3 patients at baseline and after
18 months of ERT. In all patients, the P-R interval was
normal at the beginning of the study and remained un-
changed. In Pt 1, atrial fibrillation persisted. On echocar-
diography, mild mitral insufficiency remained stable in
all patients, as did valve dysfunction. Pts 1 and 3 im-
proved mildly to markedly in all other echocardiographic
parameters. In Pt 2, EF and EDD remained essentially
stable, but ST, PWT, and LVM was mildly to moderately
worsened.
Specifically, over 18 months of ERT, cardiac contractil-
ity, as reflected by left ventricular EF, markedly improved
to normal in Pt 1, moderately improved from low normal
in Pt 3, and remained normal in Pt 2. EDD stayed es-
sentially stable at moderately abnormal values in every
case. Interventricular ST, PWT, and LVM were very high
in all patients at baseline. At 18 months, ST slightly im-
proved in Pts 1 and 3, but moderately worsened in Pt 2; a
similar pattern of responses was seen in PWT. LVM de-
creased markedly in Pts 1 and 3, but increased even more
markedly in Pt 2.
In general, echocardiographic response between
months 12 and 18 continued to broaden in Pt 1, but
plateaued in Pt 3. However, Pt 2 mildly to moderately
improved in all echocardiographic parameters except mi-
tral insufficiency and ST between baseline and month 12,
but worsened mildly to markedly in all echocardiographic
parameters except EDD in the following 6 months of
observation.
Safety
In Pts 1 and 3, agalsidase beta has remained well tol-
erated over the first year and a half of ERT. After the
second enzyme infusion, Pt 2 experienced an episode
of gastroenteritis accompanied by functional acute renal
failure that did not require hemodialysis. However, these
adverse events were attributed to a viral infection and
consequent dehydration rather than to ERT and were
treated by vigorous fluid infusion. They resolved within
7 days and ERT was reintroduced 5 months later without
any complications to date.
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DISCUSSION
In patients with Fabry disease, the successfully en-
grafted kidney from a nonaffected donor generally pos-
sesses sufficient a-Gal-A activity to prevent renal storage
of Gb3 and even to improve some extra-renal symptoms
such as pain, hypohydrosis, and acroparesthesia [7, 8, 10,
21]. The absence of glycosphingolipid accumulation in
the allograft, and, in particular, tubular cells, probably
explains the undetectability of Gb3 in our patients’ urine.
However, the a-Gal-A activity of the allograft appears
to be insufficient to appreciably increase the absent or
very low native systemic enzyme concentration [7, 8,
21]. Thus, general opinion holds that the allograft alters
neither the systemic substrate deposition nor the pro-
gression of important systemic complications of Fabry
disease [3], and our patients’ cases support this opinion.
In fact, although less frequent and severe in transplantees
than in hemodialysis patients [9, 11], cardiovascular and
cerebrovascular complications are common, frightening
sources of morbidity and the primary causes of mortal-
ity in long-term normally functioning transplant patients
with Fabry disease [12, 13]. The need to address extra-
renal involvement in this population prompted us to ini-
tiate this pilot trial of ERT in 3 such individuals with
normal P-R intervals on electrocardiography, but severe
Fabry cardiomyopathy documented by biopsy and/or
echocardiography.
In our trial, a relatively short course of agalsidase beta
(18 months in Pt 1 and Pt 3, 13 months in Pt 2) showed
clear metabolic, morphologic, and clinical/functional effi-
cacy against extra-renal manifestations of Fabry disease.
Although we did not perform biopsies and histologic
analysis, plasma Gb3 determination showing 23% to 50%
reduction suggests that the enzyme cleared a large quan-
tity of glycosphingolipids from extra-renal tissues in each
patient. Echocardiography demonstrated an appreciable
reduction in LVM and mild improvement or stabilization
of all other morphologic parameters assessed in the 2 of 3
patients who received essentially the full planned course
of infusions. Clinical/functional response included rapid
resolution of extremity pain in Pt 1, and proteinuria in
Pt 3, as well as heightened contractility, reflected by in-
creased EF in all patients. Cardiac response, however, was
not uniform. Severe arrhythmia persisted in the patient
with that complication and mild mitral insufficiency, in all
3 patients. From baseline to 18 months, Pt 2 moderately to
markedly worsened in all evaluated morphologic param-
eters except EDD, despite having registered a moderate
improvement in LVM between baseline and 12 months.
Of interest, this individual had a 5-month interruption in
treatment after the initial month of infusions and conse-
quently received a substantially lower total dose of en-
zyme than did the other patients.
Nonuniform cardiac response to a short course of ERT
at 1 mg/kg every 2 weeks also was seen in a recent large,
randomized multicenter Phase III/Extension study [16].
In that study, histologic analysis demonstrated that 6 to 12
months of ERT cleared Gb3 from the cardiac microvas-
culature in 67% to 82% of patients, but did not change
electrocardiographic and echocardiographic findings.
At least 4 factors may explain this nonuniform car-
diac response. First, the endomyocardium has dramat-
ically higher Gb3 concentrations than do tissues from
other organs [22], which may make cardiac Gb3 accumu-
lation a particularly challenging therapeutic target. Sec-
ond, there may be variation between patients, between
sites within organs, and between cell and tissue types,
in the “tipping point” at which Gb3 accumulation me-
diates irreversible end-organ damage. Similar variation
may exist in the “tipping point” when changes in Gb3
accumulation, whether from progressive deposition or
ERT-mediated removal, begin to evince radiologic/
clinical effects. In addition, enzyme may not be evenly
delivered within the body. Possibly reflecting variation in
tissue Gb3 concentration and accessibility to enzyme, our
patients with allograft kidneys and severe cardiac com-
plications had lesser plasma Gb3 reduction than did most
of the Phase III/Extension patients, who had native, func-
tional kidneys and apparently lacked clinical cardiac com-
plications [22]. Supporting the “tipping point” concept, as
well as the clinical relevance of this marker, plasma Gb3
reduction was substantially higher (50% and ∼48%) in
our patients with echocardiographic response than in our
echocardiographic nonresponder (∼23%).
A third possible explanation for the nonuniform car-
diac response in our study is that patients with chronic
renal failure (CRF) may have secondary cardiopathy,
which would not be expected to respond to treatment
of the underlying genetic disorder, and thus, could con-
found interpretation of cardiac response to ERT. The lack
of improvement of arrhythmia in Pt1 and the progres-
sion of morphologic abnormalities in Pt 2 despite treat-
ment indeed lead us to think that in our patients, either
the conduction tissue or the cardiomyocytes have been
permanently damaged by CRF and/or Gb3 storage. A
hypothetical mechanism for Fabry-related damage is
residual disarrangement and fibrosis in myocardial fine
architecture caused by impaired myofibrillar recovery
and patching in response to Gb3 accumulation [4]. Lastly,
an explanation for nonuniform cardiac response in both
our trial and the Phase III/Extension study may lie in a
dose-response effect of ERT in cardiac glycosphingolipid
clearance, which has been observed in animal and Phase
I/II clinical trials [22, 23].
It is possible that intermeasurement variability has in-
fluenced our echocardiographic results. However, we be-
lieve that the use of the same standard criteria, operator,
and equipment for all scans in each patient, as well as the
magnitude of many of the changes observed, renders this
somewhat unlikely.
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Together, our echocardiographic results and their pos-
sible explanatory factors may argue for evaluation of
longer courses and higher doses of ERT in patients with
Fabry cardiac complications, as well as initiation of ERT
at the earliest possible stage of Fabry disease. It should
be noted, however, that even if initiated after irreversible
Fabry end-organ damage has occurred, ERT could either
prevent or attenuate further such damage. In addition
to clinical studies, histologic and ultrastructural analy-
ses should be conducted to explore the mechanisms and
natural history of Fabry cardiac complications and their
response to ERT.
Our study also has demonstrated the safety of ERT in
kidney transplant patients with Fabry disease. Restora-
tion of renal function by the kidney transplant has been
preserved so that no alteration was necessary in any pa-
tient’s immunosuppressive regimen. After a combined
total of 116 infusions, no treatment-related adverse re-
actions or intolerance or seroconversion were recorded.
This finding probably is attributable to our patients re-
ceiving immunosuppressive therapy, because this finding
differs from the experience in Fabry patients with unsup-
pressed immunity [16, 18].
An interesting observation of our study relating to the
source of plasma Gb3 and to the interpretation of plasma
Gb3 concentration as a marker of tissue glycosphingolipid
clearance is that baseline plasma Gb3 levels in kidney
transplant patients were approximately one half to two
thirds lower than concentrations noted in patients with
their native kidneys, albeit by a different assay method.
This suggests an important contribution of kidney Gb3
accumulation to plasma Gb3 concentration.
CONCLUSION
Our preliminary experience demonstrates that ERT
with agalsidase beta at a dose of ∼1 mg/kg every 2 weeks
is safe and often effective against extra-renal Fabry in-
volvement in kidney transplant patients with Fabry dis-
ease. Studies of longer courses at this and higher doses
are merited to verify and possibly improve the long-term
cardiac effects of ERT in this genetic disorder.
ACKNOWLEDGMENTS
Editorial assistance on this paper was provided through an unre-
stricted educational grant from Genzyme Europe B.V., Naarden, The
Netherlands.
Reprint requests to Renzo Mignani, M.D., Department of Nephrology
and Dialysis, Infermi Hospital, via Settembrini 2, 47900 Rimini, Italy.
E-mail: rmignani@auslrn.net.
REFERENCES
1. DESNICK RJ, IOANNOU YA, ENG CM: a-galactosidase A deficiency:
Fabry disease, in The Metabolic and Molecular Bases of Inherited
Disease, 8th ed, edited by Scriver CR, Beaudet AL, Sly WS, et al,
New York, McGraw-Hill, 2001, pp 3733–3774
2. BRANTON M, SCHIFFMANN R, LOPP JB: Natural history and treat-
ment of renal involvement in Fabry disease. J Am Soc Nephrol
13(Suppl):S134–S138, 2002
3. DESNICK RJ, BANIKAZEMI M, WASSERSTEIN M: Enzyme replace-
ment therapy in Fabry’s disease, an inherited nephropathy. Clinical
Nephrology 57:1–8, 2002
4. KAMPMANN C, BAEHNER F, RIES M, BECK M: Cardiac involvement in
Anderson-Fabry disease. J Am Soc Nephrol 13(Suppl):S147–S149,
2002
5. LINHART A, PALCEK T, BULTAS J, et al: New insights in cardiac struc-
tural changes in patients with Fabry’s disease. Am Heart J 139:1101–
1108, 2000
6. GOLDMAN ME, CANTOR R, SCHWARTZ MF, et al: Echocardiographic
abnormalities and disease severity in Fabry’s disease. J Am Coll
Cardiol 7:1157–1161, 1986
7. FRIEDLAENDER MM, KOPOLOVIC J, RUBINGER D, et al: Renal biopsy
in Fabry’s disease eight years after successful renal transplantation.
Clin Nephrol 27:206–211, 1987
8. MIGNANI R, GERRA D, MALDINI L, et al: Long-term survival of pa-
tients with renal transplantation in Fabry’s disease. Contrib Nephrol
136:229–233, 2001
9. OJO A, MEIER-KRIESCHE HU, FRIEDMAN G, et al: Excellent outcome
of renal transplantation in patients with Fabry’s disease. Transplan-
tation 69:2337–2339, 2000
10. PECES R, AGUADO S, FERNANDEZ F: Renal transplantation in Fabry’s
disease. Nephron 51:294–295, 1989
11. TSAKIRIS D, SIMPSON HKL, JONES EHP, et al: Rare diseases in renal
replacement therapy in the ERA-EDTA Registry. Nephrol Dial
Transplant 11(Suppl 7):4–20, 1996
12. BANNWART F: Morbus Fabry: Licht- und elektronenmikroskopis-
cher herzbefund12 jahre nach erfolgreicher nierentransplantation.
Schweiz Med Wschr 112:1742–1747, 1982
13. KRAMER W, THORMANN J, MUELLER K, FRENZEEL H: Progressive
cardiac involvement by Fabry’s disease despite successful renal al-
lotransplantation. Int J Cardiol 7:72–75, 1985
14. DESNICK RJ, WASSERSTEIN MP: Fabry’s disease: Clinical features
and recent advances in enzyme replacement therapy. Advances in
Nephrology 21:317–339, 2001
15. THADHANI R, WOLF M, WEST ML, et al: Patients with Fabry dis-
ease on dialysis in the United States. Kidney Int 61:249–255,
2002
16. ENG CM, GUFFON N, WILCOX WR, et al: Safety and efficacy of recom-
binant human a-galactosidase A replacement therapy in Fabry’s
disease. N Engl J Med 345:9–16, 2001
17. THURBERG BL, RENNKE HL, COLVIN RB, et al: Globotriaosylce-
ramide accumulation in the Fabry kidney is cleared from multiple
cell types after enzyme replacement therapy. Kidney Int 62:1933–
1946, 2002
18. SCHIFFMAN R, KOPP JB, AUSTIN HA, et al: Enzyme replacement
therapy in Fabry’s disease. A randomized controlled trial. JAMA
285:2743–2749, 2001
19. BOSCARO F, PIERACCINI G, LA MARCA G, et al: Rapid quantifica-
tion of globotriaosylceramide in human plasma and urine: A po-
tential application for monitoring enzyme replacement therapy in
Anderson-Fabry disease [Rapid Communication]. Mass Spectrom
16:1507–1514, 2002
20. RICHARDS SM, OLSON TA, MCPHERSON JM: Antibody response
in patients with Gaucher disease after repeated infusion with
macrophage targeted glucocerebrosidase. Blood 82:1402–1409,
1993
21. ERTEN Y, OZDEMIR FN, DEMIRHAN B, et al: A case of Fabry’s dis-
ease with normal kidney function at 10 years after successful renal
transplantation. Transplant Proc 30:842–843, 1998
22. ENG CM, BANIKAZEMI M, GORDON RE, et al: A Phase 1/2 clinical
trial of enzyme replacement in Fabry disease: Pharmacokinetics,
substrate clearance and safety studies. Am J Human Genet 68:711–
722, 2001
23. IOANNOU YA, ZEIDNER KM, GORDON RE, DESNICK RJ: Fabry dis-
ease: Preclinical studies demonstrate the effectiveness of alpha-
galactosidase A replacement in enzyme-deficient mice. Am J Hum
Genet 69:14–25, 2001
